Cargando…
Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies
Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379219/ https://www.ncbi.nlm.nih.gov/pubmed/35972721 http://dx.doi.org/10.1007/s12325-022-02257-4 |
_version_ | 1784768630354870272 |
---|---|
author | Burns, Leah Kalesnik-Orszulak, Robert Spring, Rick Zeegers, Fabienne Rutstein, Mark Hukkelhoven, Mathias Wruck, Lisa O’Donnell, John |
author_facet | Burns, Leah Kalesnik-Orszulak, Robert Spring, Rick Zeegers, Fabienne Rutstein, Mark Hukkelhoven, Mathias Wruck, Lisa O’Donnell, John |
author_sort | Burns, Leah |
collection | PubMed |
description | Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to identify appropriate use cases. An interactive tool was developed (“Decision Aid,” https://sn.pub/TpDjZx) to assist researchers, industry, and other stakeholders in identifying regulatory situations that can benefit from leveraging RWE by organizing precedent cases based on a given regulatory objective (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) and type of RWE study design (external control, observational study, pragmatic trial). Key success factors ensuring fit-for-purpose data and rigorous methods (e.g., clear endpoints, minimizing bias, data completeness) are also described. The tool allows the user to navigate through the precedent cases by selecting certain regulatory objectives and/or study designs. The Decision Aid supports regulatory activities in the RWE space and encourages further use of RWE in regulatory decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02257-4. |
format | Online Article Text |
id | pubmed-9379219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-93792192022-08-16 Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies Burns, Leah Kalesnik-Orszulak, Robert Spring, Rick Zeegers, Fabienne Rutstein, Mark Hukkelhoven, Mathias Wruck, Lisa O’Donnell, John Adv Ther Original Research Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to identify appropriate use cases. An interactive tool was developed (“Decision Aid,” https://sn.pub/TpDjZx) to assist researchers, industry, and other stakeholders in identifying regulatory situations that can benefit from leveraging RWE by organizing precedent cases based on a given regulatory objective (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) and type of RWE study design (external control, observational study, pragmatic trial). Key success factors ensuring fit-for-purpose data and rigorous methods (e.g., clear endpoints, minimizing bias, data completeness) are also described. The tool allows the user to navigate through the precedent cases by selecting certain regulatory objectives and/or study designs. The Decision Aid supports regulatory activities in the RWE space and encourages further use of RWE in regulatory decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02257-4. Springer Healthcare 2022-08-16 2022 /pmc/articles/PMC9379219/ /pubmed/35972721 http://dx.doi.org/10.1007/s12325-022-02257-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Burns, Leah Kalesnik-Orszulak, Robert Spring, Rick Zeegers, Fabienne Rutstein, Mark Hukkelhoven, Mathias Wruck, Lisa O’Donnell, John Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies |
title | Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies |
title_full | Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies |
title_fullStr | Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies |
title_full_unstemmed | Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies |
title_short | Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies |
title_sort | real world-evidence for regulatory use decision aid: an interactive tool to inform clinical development and regulatory strategies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379219/ https://www.ncbi.nlm.nih.gov/pubmed/35972721 http://dx.doi.org/10.1007/s12325-022-02257-4 |
work_keys_str_mv | AT burnsleah realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT kalesnikorszulakrobert realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT springrick realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT zeegersfabienne realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT rutsteinmark realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT hukkelhovenmathias realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT wrucklisa realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies AT odonnelljohn realworldevidenceforregulatoryusedecisionaidaninteractivetooltoinformclinicaldevelopmentandregulatorystrategies |